The application of remidazolam combined with esketamine in hysteroscopic surgery: a randomized controlled trial.

The application of remidazolam combined with esketamine in hysteroscopic surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041088

Enrollment

Unknown

Registered

2020-12-17

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial polyp

Interventions

remidazolam and esketamine group:remidazolam and esketamine

esketamine and propofol group:esketamine and propofol

sufentannil and propofol group:sufentannil and propofol

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with definite indications for hysteroscopic surgery; (2) > : 18 years old; Participate in this study voluntarily and the informed consent is signed by the patient; (3) BMI 18-27.5kg/m; (4) ASA Level I-II.

Exclusion criteria

Exclusion criteria: (1) Patients with acute upper respiratory tract infection, asthmatic attack stage or acute severe laryngeal disease; (2) patients with hypotension (Bp 150/90mmhg); (3) Pathologically obese patients with unknown causes; (4) Patients with liver dysfunction (Child-pugh Grade B); (5) Patients with acute massive hemorrhage or perforation of the upper digestive tract; (6) Patients with heart disease such as severe arrhythmia, myocardial infarction 10mol/L).

Design outcomes

Primary

Measure	Time frame
heart rate;blood pressure;respiratory rate;SpO2;PetCO2;BIS;	—

Countries

China

Contacts

Public ContactZhang Yanzhuo

Liuzhou Workers Hospital

zhangyanzhuo625@sina.com+86 17745126625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026